Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has gained exclusive worldwide rights to a class of compounds developed by Bayer Healthcare called DGAT-1 inhibitors that have potential for the treatment of obesity, diabetes and related disorders.
Subscribe to our email newsletter
DGAT-1 inhibitors modify lipid metabolism. The lead compound in the class, BAY 74-4113, is currently in phase I clinical development.
Under the terms of the agreement, Bayer will receive an upfront fee, milestone payments and royalties on sales of any compounds successfully commercialized. Specific financial terms were not disclosed.
The agreement is subject to Hart-Scott-Rodino approval, but is expected to close in the second half of 2006.
“Obesity and diabetes are expanding hand-in-hand at near epidemic levels throughout the world. The need for new treatment options for patients has never been greater,” said Dr Martin Mackay, senior vice president, Worldwide Research & Technology for Pfizer. “We are excited about the potential of the DGAT-1 inhibitors in the areas of obesity and type 2 diabetes which complement Pfizer’s ongoing metabolic disease research programs.”